Therefore, adding NGR1 to paclitaxel could produce an additive or synergistic on the cancer itself but at the same time protect against neuropathy induced by paclitaxel, a common side effect of paclitaxel that significantly affects the patients’ quality of life. This evidence concerns the gene RTN4R and neuropathy.